Antimicrobial activity of high-proportion cefepime-tazobactam (WCK 4282) against a large number of gram-negative isolates collected worldwide in 2014

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 4, 2017, Pages

  Sader, Helio S ^a   Castanheira, Mariana ^a   Mendes, Rodrigo E ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Cefepime tazobactam

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; THIENAMYCIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; BROTH DILUTION; CHINA; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; MIC50; MIC90; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; UNITED STATES; ANALOGS AND DERIVATIVES; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; THIENAMYCINS;

EID: 85017035614     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02409-16     Document Type: Article

References (22)

1. Food and Drug Administration. 2015. Maxipime package insert. Food and Drug Administration, Rockville, MD. Accessed 2 September 2016.
2. Barradell LB, Bryson HM. 1994. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 47:471-505.
3. Sader HS, Fritsche TR, Jones RN. 2005. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagn Microbiol Infect Dis 52:265-273. https://doi.org/10.1016/j.diagmicrobio.2005.02.003.
4. Endimiani A, Perez F, Bonomo RA. 2008. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther 6:805-824. https://doi.org/10.1586/14787210.6.6.805.
5. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN. 2013. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa. I. Cephalosporins and aztreonam. Clin Infect Dis 56:1301-1309. https://doi.org/10.1093/cid/cit017.
6. Clinical and Laboratory Standards Institute. 2014. M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2016. M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Muller AE, Bhagwat S, Patel M, Mouton JW. 2016. Development of a population pharmacokinetic model of cefepime, abstr Sunday-498. Abstr ASM Microbe, Boston, MA.
9. Muller AE, Bhagwat S, Patel M, Mouton JW. 2016. Development of a population pharmacokinetic model of tazobactam including high doses, abstr Sunday-500. Abstr ASM Microbe, Boston, MA.
10. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 55:2390-2394. https://doi.org/10.1128/AAC.01737-10.
11. Nguyen HM, Shier KL, Graber CJ. 2014. Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 69:871-880. https://doi.org/10.1093/jac/dkt450.
12. Burgess SV, Mabasa VH, Chow I, Ensom MH. 2015. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review. Ann Pharmacother 49:311-322. https://doi.org/10.1177/1060028014564179.
13. Akova M, Yang Y, Livermore DM. 1990. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed class I beta-lactamases. J Antimicrob Chemother 25:199-208. https://doi.org/10.1093/jac/25.2.199.
14. Livermore DM, Mushtaq S, Warner M, Woodford N. 2016. WCK 4282 (high-dose cefepime-tazobactam) against multi-resistant Gram-negative bacteria, abstr P1265. Abstr 26th Eur Congr Clin Microbiol Infect Dis, Amsterdam, Netherlands.
15. Cordonnier C, Herbrecht R, Pico JL, Gardembas M, Delmer A, Delain M, Moreau P, Ladeb S, Nalet V, Rollin C, Gres JJ. 1997. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infect Dis 24:41-51.
16. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. 2013. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 56:272-282. https://doi.org/10.1093/cid/cis857.
17. Kim PW, Wu YT, Cooper C, Rochester G, Valappil T, Wang Y, Kornegay C, Nambiar S. 2010. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51:381-389. https://doi.org/10.1086/655131.
18. Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. 2006. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 58:987-993. https://doi.org/10.1093/jac/dkl349.
19. Sader HS, Farrell DJ, Flamm RK, Jones RN. 2014. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized with pneumonia in United States and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 43:328-334. https://doi.org/10.1016/j.ijantimicag.2014.01.007.
20. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
21. EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters, version 6.0. http://www.eucast.org/clinical-breakpoints/. Accessed January 2016.
22. Ross JE, Huband MD, Flamm RK, Jones RN, Sader HS. 2016. WCK 4282 (cefepime-tazobactam) MIC quality control ranges using a multi-laboratory study design, abstr P0806. Abstr 26th Eur Congr Clin Microbiol Infect Dis, Amsterdam, Netherlands.